SEC / FDA / FTC Regulatory Watch Content Archive

23 posts · Page 1 of 1

1. SEC/FDA/FTC Regulatory Watch — Week of May 19–27, 20262026-05-28
2. SEC/FDA/FTC Regulatory Watch — Week of May 28–June 1, 20262026-06-01
3. SEC/FDA/FTC Regulatory Watch — Week of June 2–8, 20262026-06-08
4. SEC/FDA/FTC Regulatory Watch — Week of June 9–15, 20262026-06-15
5. SEC, FDA and FTC Watch: Swap-market comments, drug access moves, and merger remedies2026-06-22
6. SEC/FDA/FTC Regulatory Watch — Week of June 23–29, 20262026-06-29
7. SEC/FDA/FTC Regulatory Watch — Week of June 30-July 6, 20262026-07-06
8. SEC/FDA/FTC Regulatory Watch: E-Delivery, oral PCSK9 approval, and HSR penalties (July 13-19, 2026)2026-07-20
9. SEC/FDA/FTC Regulatory Watch: 24-hour trading, food-color rules, and consumer remedies (July 20–26, 2026)2026-07-27
10. SEC's $152M investor case, FDA's freeze-dried plasma, and FTC's health-data suit (July 27–August 2, 2026)2026-08-03
11. SEC accounting unit, FDA's three product actions, and FTC's disparate-impact policy (August 3-9, 2026)2026-08-10
12. SEC fraud docket, FDA animal-drug EUA, and FTC consumer redress (August 10-16, 2026)2026-08-17
13. Crypto rulebook, Genglycos, and FTC pricing scrutiny — August 17–23, 20262026-08-24
14. SEC false adviser filings, FDA approvals, and FTC final orders - August 24-30, 20262026-08-31
15. SEC subpoenas, FDA approvals, and FTC pricing deadline — September 1–7, 20262026-09-07
16. SEC Ponzi actions, FDA dual approvals, and FTC $12M processor ban — September 8–14, 20262026-09-14
17. SEC tokenized-stock exemption, FDA first-in-class approvals, and a $225M Amway order — September 15–21, 20262026-09-21
18. SEC control failures, FDA's nonclinical-testing rule, and a $127M truck-leasing Ponzi — September 22–28, 20262026-09-28
19. Crypto custody, private-market access, and the FTC's first Robinson-Patman settlement in a generation — September 29–October 5, 20262026-10-05
20. Cross-trading at the SEC, two cherry-picking cases, and the FTC's price-transparency push — October 6–12, 20262026-10-12
21. Cross-trading's deadline, an approval built on another approval, and 18.5 million tickets — October 13–19, 20262026-10-19
22. Examiners' priority list, a $106.8 million judgment, and the first antisense hepatitis B drug — October 20–26, 20262026-10-26
23. Infant formula limits, a $200 million crypto complaint, and nine companies asked how they price — October 27–November 2, 20262026-11-02

Explore more channels on Discover